 After a fiasco surrounding the contamination of COVID-19 vaccine doses in its facilities, Emergent BioSolutions Incs NYSE: EBS manufacturing deal with the US government has come to an end. CEO Bob Kramer said that the two parties mutually agreed to terminate the contract, evaporating about 180 million in deal value. 